Why the study?
Sex-based differences in TAVR outcomes have been documented, but whether they persist with contemporary third generation transcatheter heart valves remains unknown.
Does female sex worsen in-hospital mortality and complications in patients undergoing TAVR with contemporary third generation transcatheter heart valves?
Observational (n=44,280)
Yes
Does female sex worsen in-hospital mortality and complications in patients undergoing TAVR with contemporary third generation transcatheter heart valves?
Despite the use of contemporary third-generation transcatheter heart valves, female patients undergoing TAVR continue to face higher in-hospital mortality and complication rates than males.
Answers are grounded in this paper and cite their sources.
May support sex-specific risk assessment in TAVR; leaves open whether contemporary valves mitigate or perpetuate sex disparities.
BACKGROUND: Sex-based differences in transcatheter aortic valve replacement (TAVR) outcomes have been previously documented. However, whether these differences persist with contemporary third generation transcatheter heart valves (THVs) is unknown. METHODS: We utilized Vizient's clinical database/resource manager (CDB/RM™) to identify patients who underwent TAVR between January 1, 2018 and March 31, 2020 to compare in-hospital outcomes between males and females. The primary endpoint was in-hospital mortality. Secondary endpoints included key in-hospital complications, length of stay, discharge disposition, and cost. Unadjusted, propensity-score matched and risk-adjusted analyses of outcomes were performed. RESULTS: During the study period, 44,280 patients (24,842 males, 19,438 females) underwent TAVR. The primary endpoint of in-hospital mortality was higher in females than in males (1.6 vs. 1.1% p < .001) in unadjusted analysis and persisted following propensity matching (1.6 vs. 0.9%, p < .001) and multivariable logistic regression with various risk-adjustment models. In the most comprehensive model adjusting for age, race, and clinical comorbidities, female sex was associated with 34% greater odds of in-hospital death (95% CI 20-50%, p < .001). Unadjusted and risk-adjusted rates of post-TAVR stroke, vascular complication, and blood transfusion were higher in females. Moreover, females demonstrated longer hospitalizations, higher costs and reduced rates of independent discharge home. CONCLUSION: Sex-based differences in TAVR in-hospital outcomes persist in contemporary practice with third generation transcatheter heart valves. Further research is needed to assess the reasons for these observed disparities and to identify effective mitigation strategies.
No takes yet. Share an insight, caveat, or question.
Simard et al. (2021) conducted an observational in Transcatheter aortic valve replacement (n=44,280). Female sex vs. Male sex was evaluated on In-hospital mortality (OR 1.34, 95% CI 1.20-1.50, p=< .001).
Synapse has enriched 10 related papers. Consider them for comparative context: